. Author manuscript; available in PMC: 2023 Aug 7.

Published in final edited form as: J Rheumatol. 2021 Dec 1;49(3):274–280. doi: 10.3899/jrheum.210332

Table 2.

Results from multivariable analyses for the association of TNFi use and the development of incident hypertension in an AS cohort.

	Adjusted HR	95% CI

Main analysis using MSM (n = 630)
With BASDAI	1.10	0.83–1.37
With ASDAS	1.09	0.84–1.34
Without BMI	1.10	0.84–1.36
Complete case analysis using MSM (n = 618)^a
With BASDAI	1.35	1.09–1.69
With ASDAS	1.34	1.08–1.67
Conventional regression analysis^b, multiply imputed (n = 630)
Univariable	1.04	0.73–1.47
Multivariable	1.08	1.01–1.16
Conventional regression analysis, complete case (n = 618)^a
Univariable	1.03	0.73–1.47
Multivariable	1.09	1.01–1.17

Complete-case analysis did not include BMI as a covariate due to degree of missingness. This analysis included 618 participants with 4152 observations, compared to 5393 observations for 630 participants in the multiply imputed main analyses.

Cox proportional hazards models with time-varying exposure (TNFi use). AS: ankylosing spondylitis; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Activity Index; MSM: marginal structural model; TNFi: tumor necrosis factor inhibitor.